Short Interest in Vincerx Pharma, Inc. (NASDAQ:VINC) Increases By 22.6%

Vincerx Pharma, Inc. (NASDAQ:VINC) was the recipient of a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 735,400 shares, an increase of 22.6% from the November 15th total of 600,000 shares. Based on an average trading volume of 607,900 shares, the short-interest ratio is presently 1.2 days.

Institutional Investors Weigh In On Vincerx Pharma

Large investors have recently modified their holdings of the stock. Armistice Capital LLC acquired a new position in shares of Vincerx Pharma in the 2nd quarter worth $1,610,000. Marshall Wace LLP boosted its position in shares of Vincerx Pharma by 359.1% in the 2nd quarter. Marshall Wace LLP now owns 328,533 shares of the company’s stock valued at $266,000 after purchasing an additional 256,967 shares during the period. Finally, Vanguard Group Inc. boosted its position in shares of Vincerx Pharma by 29.9% in the 1st quarter. Vanguard Group Inc. now owns 666,995 shares of the company’s stock valued at $3,375,000 after purchasing an additional 153,575 shares during the period. 44.02% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, Leerink Partners cut their price target on shares of Vincerx Pharma from $4.00 to $2.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th.

Vincerx Pharma Stock Performance

Shares of NASDAQ:VINC opened at $0.19 on Friday. The stock has a market capitalization of $6.43 million, a price-to-earnings ratio of -0.19 and a beta of 1.48. Vincerx Pharma has a 1-year low of $0.18 and a 1-year high of $9.37. The company has a 50 day moving average price of $0.32 and a 200 day moving average price of $0.56.

About Vincerx Pharma

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.